Oric Pharmaceuticals
Daniel Shore has extensive experience in the field of medicinal chemistry, currently serving as a Senior Scientist at ORIC Pharmaceuticals Inc. since April 2021, following a position as a Scientist in the same department. Prior roles include Senior Research Associate II at Gilead Sciences from May 2019 to March 2021, and a decade-long tenure at Genentech from August 2009 to April 2019 encompassing various roles, including Senior Scientific Researcher and Research Associate in Discovery Chemistry. Earlier experience also includes a summer internship at Merck-Frosst in 2007. Academic credentials include a Master’s degree in Organic Chemistry and a Bachelor’s degree in Chemistry, both obtained from the University of Ottawa.
This person is not in the org chart
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.